BUZZ-Hansoh jumps most in 19 months on annual profit beat, Citi lifts target price

Reuters03-31
BUZZ-Hansoh jumps most in 19 months on annual profit beat, Citi lifts target price

** Shares of China's Hansoh Pharmaceutical Group 3692.HK jump 8.6% to HK$35.94, on track for biggest one-day pct gain since August 2024

** Stock hits the highest point since February 24 in the third straight session of gains; top pct gainer in the Hang Seng Biotech Index .HSBIO, which slips 0.2%

** Hansoh, a Roche ROG.S partner, reports a 27% y/y rise in 2025 annual profit, beating market expectations and boosted by income from innovative medicines and business development deals

** Citi maintains "buy" rating on Hansoh and lifts target price to HK$49 from HK$45 as it raises FY26/27E revenue forecasts by 8%/9% to reflect latest sales trend and business development collaboration revenue

** YTD, stock down 1.4%, benchmark Hang Seng Index .HSI down 3.7%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment